Current Status
Not Enrolled
Price
Free
Get Started

Program Director

Khalid Al Rasadi, MD

Program Director

Raul D Santos, MD, MSc, PhD

2020 Middle East Summit on Residual Cardiovascular Risk

Cardiovascular diseases remain the #1 cause of death and disability globally and are on the rise in developing regions of the world. Despite advances in the control of the classic risk factors like lowering LDL-Cholesterol and efforts to manage contributing disease factors such as diabetes, obesity and hypertension, patient risk for developing ASCVD can still remain high. This course was designed to educate on the complete examination and clinical approaches to the treatment of residual risk (RR) factors that may persist and ultimately continue to drive the patient’s potential for cardiovascular events.

The IAS is pleased to present thirteen (13) recordings from the live accredited sessions presented at the 2020 Middle East Residual Risk Cardiovascular Summit held in Dubai on February 21-22, 2020. This comprehensive educational event was designed for medical professionals in the clinical setting.

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the speakers and participants for sharing their experience and for helping IAS to develop this global faculty of experts featured in the presentations.

Pre-activity information

Not available

Dextran Sulphate Lipoprotein Apheresis in FH and Beyond – Tiziana Sampietro, Italy

See more...

Not available

Clinical Case 3: Familial Hypercholesterolemia Homozygous Null Mutations – Zuhier Awan, KSA

See more...

Not available

Kuwait Audience Participant Survey

See more...

Not available

Clinical Case 4: Treatment of Type II Familial Hypercholesterolemia by Portacaval Anastomisis: A Case Report – Faouzi Maatouk, Tunisia

See more...

Not available

Clinical Case 3: PCSK-9 Inhibitor Resistance: Case Report – Noor Al Rajhi, Kuwait

See more...

Not available

Clinical Case 2 – Homozygous Familial Hypercholesterolemia: Experience from Qatar – Tawfeg Ben-Omran, Qatar

See more...

Not available

Clinical Case 1 – LDL Apheresis in Pediatric HoFH – Mohammed Al Dubayee, KSA

See more...

Not available

The Management of Pedicatric HeFH, When and How to Treat – Albert Wiegman, Netherlands

See more...

Not available

Treatment of Severe FH – Dirk Blom, South Africa

See more...

Not available

The Management of Pediatric HoFH – Luis Masana, Spain

See more...

Not available

Diagnosis and Implications of Pediatric FH – Raul Santos, Brazil

See more...

Not available

Treatment of Severe FH: Lomitapide Copy

See more...

Not available

Treatment of Severe FH: LDL Apheresis Copy

See more...

Not available

Novel Therapies and Future Developments to Treat Severe FH Copy

See more...

Not available

Management Algorithm for Severe FH: Different Guidelines Implications Copy

See more...

Not available

A Novel Case of Homozygous LDLRAP1 Gene Mutation causing Autosomal Recessive FH in Kuwait Copy

See more...

Not available

Management of Patients with Hypercholesterolemia during COVID-19 Pandemic Copy

See more...

Not available

Dextran Sulphate Lipoprotein Apheresis in FH and Beyond

See more...

Not available

Familial Hypercholesterolemia Homozygous Null Mutations Copy

See more...

Not available

Clinical Cases of Lipidology Copy

See more...

« » page 1 / 5